This is consistent with the proposed HER3-DUSP6 positive feedback mechanism, as HER3 or NRG overexpression confer resistance to several cancer drugs (Erjala et al, 2006; Haikala and Janne, 2021; Knuefermann et al, 2003; Recondo et al, 2020; Wilson et al, 2012; Yonesaka et al, 2011). Here, ERBB3 is linked to cancer.